GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Cyclically Adjusted FCF per Share

Ryvu Therapeutics (WAR:RVU) Cyclically Adjusted FCF per Share : zł0.00 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ryvu Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was zł-1.943. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is zł0.00 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ryvu Therapeutics was -14.20% per year. The lowest was -14.20% per year. And the median was -14.20% per year.

As of today (2025-05-24), Ryvu Therapeutics's current stock price is zł30.00. Ryvu Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was zł0.00. Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Ryvu Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Ryvu Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Cyclically Adjusted FCF per Share Chart

Ryvu Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -2.24 -2.30 -2.75 -3.34

Ryvu Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 -3.06 -3.22 -3.34 -

Competitive Comparison of Ryvu Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Ryvu Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ryvu Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.943/157.0208*157.0208
=-1.943

Current CPI (Mar. 2025) = 157.0208.

Ryvu Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.376 100.448 -0.588
201509 -0.435 99.634 -0.686
201512 -0.735 99.471 -1.160
201603 0.051 98.983 0.081
201606 -0.557 99.552 -0.879
201609 -0.196 99.064 -0.311
201612 -1.207 100.366 -1.888
201703 -1.720 101.018 -2.674
201706 2.037 101.180 3.161
201709 -0.436 101.343 -0.676
201712 -0.619 102.564 -0.948
201803 -0.554 102.564 -0.848
201806 0.351 103.378 0.533
201809 -0.586 103.378 -0.890
201812 -1.971 103.785 -2.982
201903 -2.067 104.274 -3.113
201906 1.247 105.983 1.848
201909 -0.660 105.983 -0.978
201912 -1.113 107.123 -1.631
202003 -1.284 109.076 -1.848
202006 -0.583 109.402 -0.837
202009 -0.559 109.320 -0.803
202012 -0.306 109.565 -0.439
202103 -0.725 112.658 -1.010
202106 -1.773 113.960 -2.443
202109 -1.212 115.588 -1.646
202112 -0.152 119.088 -0.200
202203 -1.238 125.031 -1.555
202206 -1.091 131.705 -1.301
202209 -0.282 135.531 -0.327
202212 3.293 139.113 3.717
202303 -1.523 145.950 -1.639
202306 -1.092 147.009 -1.166
202309 -0.409 146.113 -0.440
202312 -1.038 147.741 -1.103
202403 -1.904 149.044 -2.006
202406 -1.112 150.997 -1.156
202409 -1.635 153.439 -1.673
202412 -1.198 154.660 -1.216
202503 -1.943 157.021 -1.943

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Ryvu Therapeutics  (WAR:RVU) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ryvu Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines